Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
Rhea-AI Summary
Optimi Health (NASDAQ: OPTH) has produced two naturally derived microdose psilocybin finished drug products at 1 mg and 2 mg, available to authorized clinical research organizations. The capsules offer validated, consistent dosing and extend Optimi's psilocybin range, which includes a 5 mg capsule prescribed for treatment-resistant depression in Australia.
All products are manufactured end-to-end at Optimi's GMP facility in Princeton, British Columbia, under a Health Canada Drug Establishment License, for export to regulated international markets.
AI-generated analysis. Not financial advice.
Positive
- Launch of 1 mg and 2 mg microdose psilocybin finished drug products
- Standardized, validated dosing designed for controlled clinical microdosing studies
- Extension of psilocybin range alongside existing 5 mg capsule used in Australia
- End-to-end in-house GMP production under Health Canada Drug Establishment License
- Supply of psilocybin and MDMA products to regulated international markets
Negative
- None.
News Market Reaction – OPTH
On the day this news was published, OPTH declined 12.89%, reflecting a significant negative market reaction. Argus tracked a trough of -9.5% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $27.06M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Peers on Argus
No peers with momentum or same-day headlines were flagged, indicating the 5.71% move in OPTH appears stock-specific rather than part of a broader sector rotation.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 10 | Clinical trial supply | Positive | -5.0% | First export of psilocybin to UK to support a Phase 2 clinical trial. |
For clinical trial-linked updates, the prior event showed a negative price reaction despite operationally positive news.
Over recent weeks, Optimi has highlighted multiple milestones, including Australian commercial psilocybin production, higher-purity extract output, and expanded access under Australia’s Authorized Prescriber framework. On Jun 10, 2026, a clinical trial-focused export to the UK for a Phase 2 study saw shares fall 4.98%. Today’s microdose psilocybin launch adds new 1mg and 2mg formats for research, extending the 5mg capsule already used for treatment-resistant depression.
Historical Comparison
Prior clinical trial news on Jun 10 saw OPTH fall 4.98%. Today’s +5.71% rise on another clinical-research-focused update contrasts with that pattern.
Clinical activity has progressed from exporting psilocybin for a UK Phase 2 trial to broadening Optimi’s psilocybin toolkit with standardized 1mg and 2mg microdose capsules for controlled studies.
Regulatory & Risk Context
Market Pulse Summary
The stock dropped -12.9% in the session following this news. A negative reaction despite today’s microdose product launch would have fit the earlier pattern, where clinical-trial news on Jun 10 coincided with a -4.98% move. The company’s filings report revenue of only $99,500 versus a net loss of $3,145,846 and cash of $106,711, which may frame sentiment around new initiatives. Even with CAD$18.4M in recent proceeds, the stock traded below its 200-day MA and 52-week high beforehand.
Key Terms
microdosing medical
fadiman protocol medical
stamets protocol medical
gmp regulatory
active pharmaceutical ingredient (api) technical
drug establishment license (del) regulatory
AI-generated analysis. Not financial advice.
Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies
New microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in
Microdosing refers to taking low, sub-perceptual doses of a psychedelic on a repeated schedule. Common regimens include the Fadiman protocol (one day on, two days off) and the Stamets protocol (four days on, three days off), which build in rest days to limit tolerance.
CEO and Co-Founder Dane Stevens said: "Most microdosing relies on dried mushrooms, whose psilocybin content varies widely from batch to batch. Optimi's capsules instead deliver naturally derived psilocybin at a validated, consistent dose, pairing the natural source many researchers prefer with the accurate dosage that controlled research requires. The 1mg and 2mg dosage formats extend Optimi's psilocybin range, which already includes the 5 mg capsule formulation currently prescribed for treatment-resistant depression in
Optimi produces these products start to finish in-house, cultivating and harvesting the mushrooms, generating a full-spectrum mushroom extract as the active pharmaceutical ingredient (API), and formulating, encapsulating, and packaging the finished product for export to clinical research organizations. Every stage is completed on-site Optimi's wholly owned GMP facility in
Optimi supplies finished psilocybin and MDMA drug products to regulated markets internationally, supporting both patient access and clinical research. Inquiries about product supply for special access programs and clinical trials may be directed to sales@optimihealth.ca.
About Optimi Health Corp.
Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada.
Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.
For more information, please visit www.optimihealth.ca or optimi.net.
Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, including statements regarding the availability, intended use and potential benefits of the Company's 1 mg and 2 mg microdose psilocybin finished drug products, the Company's ability to supply finished psilocybin and MDMA drug products and other psychedelic drug products to qualified, authorized clinical research organizations and regulated markets internationally; the anticipated demand for, benefits of and commercial opportunities associated with the Company's psilocybin product portfolio and supply operations; the Company's ability to maintain applicable licenses, authorizations and regulatory approvals; and the Company's ability to support patient access, special access programs, authorized prescriber programs and clinical research. Forward-looking statements are often identified by words such as "expects," "anticipates," "believes," "intends," "plans," "estimates," "seeks," "may," "will," "would," "could," or similar expressions. Forward-looking statements are based on a number of assumptions and estimates and are subject to a number of known and unknown risks and uncertainties, many of which are beyond the Company's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include those described under "Risk Factors" in the Company's registration statement on Form F-1, as amended, and other filings with the U.S. Securities and Exchange Commission made from time to time, which are available at www.sec.gov and in the Company's continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.ca. These forward-looking statements reflect current expectations of management regarding future events and speak only as of the date of this press release. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement.
Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/optimi-health-launches-standardized-microdose-psilocybin-products-for-clinical-research-302802058.html
SOURCE Optimi Health Corp